TY  - JOUR
AU  - Hidalgo-Tenorio, Carmen
AU  - Vinuesa, David
AU  - Plata, Antonio
AU  - Martin-Davila, Pilar
AU  - Iftimie, Simona
AU  - Sequera, Sergio
AU  - Loeches, Belen
AU  - Lopez-Cortes, Luis Eduardo
AU  - Fariñas, Mari Carmen
AU  - Fernandez-Roldan, Concepcion
AU  - Javier-Martinez, Rosario
AU  - Muñoz, Patricia
AU  - Arenas-Miras, Maria Del Mar
AU  - Martinez-Marcos, Francisco Javier
AU  - Miro, Jose Maria
AU  - Herrero, Carmen
AU  - Bereciartua, Elena
AU  - De-Jesus, Samantha E
AU  - Pasquau, Juan
PY  - 2019
DO  - 10.1186/s12941-019-0329-6
UR  - http://hdl.handle.net/10668/15000
T2  - Annals of clinical microbiology and antimicrobials
AB  - To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and...
LA  - en
PB  - BioMed Central
KW  - Bloodstream infection
KW  - Dalbavancin
KW  - Endocarditis
KW  - Aged
KW  - Anti-Bacterial Agents
KW  - Cost-Benefit Analysis
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Endocarditis, Bacterial
KW  - Female
KW  - Gram-Positive Bacterial Infections
KW  - Humans
KW  - Length of Stay
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Sepsis
KW  - Teicoplanin
KW  - Treatment Outcome
TI  - DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
TY  - research article
VL  - 18
ER  -